Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Trial Profile

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Dec 2018 Results assessing efficacy of cabozantinib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer published in the Gynecologic Oncology
    • 31 Aug 2018 Biomarkers information updated
    • 12 Oct 2017 Planned primary completion date changed from 15 Aug 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top